- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00656136
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)
This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed.
The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment.
Patients enrolled into the trial will be treated and followed until death or lost to follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Edegem, Belgium
- 1200.23.32004 Boehringer Ingelheim Investigational Site
-
Gent, Belgium
- 1200.23.32003 Boehringer Ingelheim Investigational Site
-
Leuven, Belgium
- 1200.23.32001 Boehringer Ingelheim Investigational Site
-
Liège, Belgium
- 1200.23.32005 Boehringer Ingelheim Investigational Site
-
Namur, Belgium
- 1200.23.32006 Boehringer Ingelheim Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- 1200.23.1002 Boehringer Ingelheim Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- 1200.23.1005 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada
- 1200.23.1009 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada
- 1200.23.1001 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canada
- 1200.23.1004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Beijing, China
- 1200.23.86001 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 1200.23.86002 Boehringer Ingelheim Investigational Site
-
Beijing, China
- 1200.23.86003 Boehringer Ingelheim Investigational Site
-
Chengdu, China
- 1200.23.86009 Boehringer Ingelheim Investigational Site
-
Guangzhou, China
- 1200.23.86007 Boehringer Ingelheim Investigational Site
-
Hangzhou, China
- 1200.23.86008 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 1200.23.86004 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 1200.23.86005 Boehringer Ingelheim Investigational Site
-
Shanghai, China
- 1200.23.86006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Besançon Cedex, France
- 1200.23.3303A Boehringer Ingelheim Investigational Site
-
Besançon Cedex, France
- 1200.23.3303C Boehringer Ingelheim Investigational Site
-
Caen Cedex 5, France
- 1200.23.3305A Boehringer Ingelheim Investigational Site
-
La Tronche, France
- 1200.23.3304A Boehringer Ingelheim Investigational Site
-
La Tronche, France
- 1200.23.3304B Boehringer Ingelheim Investigational Site
-
Lyon Cedex 4, France
- 1200.23.3307A Boehringer Ingelheim Investigational Site
-
Paris, France
- 1200.23.3302A Boehringer Ingelheim Investigational Site
-
Paris, France
- 1200.23.3302B Boehringer Ingelheim Investigational Site
-
Paris cedex 20, France
- 1200.23.3301A Boehringer Ingelheim Investigational Site
-
Toulouse cedex 9, France
- 1200.23.3306A Boehringer Ingelheim Investigational Site
-
Toulouse cedex 9, France
- 1200.23.3306C Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bad Berka, Germany
- 1200.23.49010 Zentralklinik Bad Berka GmbH
-
Essen, Germany
- 1200.23.49002 Innere Klinik und Poliklinik (Tumorforschung)
-
Gauting, Germany
- 1200.23.49003 Asklepios Fachkliniken München-Gauting
-
Großhansdorf, Germany
- 1200.23.49005 Krankenhaus Großhansdorf
-
Hamburg, Germany
- 1200.23.49008 Universitätsklinik Hamburg-Eppendorf
-
Mainz, Germany
- 1200.23.49004 Johannes Gutenberg-Universität Mainz
-
Mannheim, Germany
- 1200.23.49001 Universitätsklinikum Mannheim
-
Wiesbaden, Germany
- 1200.23.49006 HSK, Dr. Horst-Schmidt-Kliniken GmbH
-
-
-
-
-
Hong Kong, Hong Kong
- 1200.23.85202 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Genova, Italy
- 1200.23.39003 Boehringer Ingelheim Investigational Site
-
Orbassano (TO), Italy
- 1200.23.39007 Boehringer Ingelheim Investigational Site
-
Perugia, Italy
- 1200.23.39002 Boehringer Ingelheim Investigational Site
-
Prato, Italy
- 1200.23.39004 Boehringer Ingelheim Investigational Site
-
Roma, Italy
- 1200.23.39008 Boehringer Ingelheim Investigational Site
-
Rozzano (MI), Italy
- 1200.23.39001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Gyeonggi-do, Korea, Republic of
- 1200.23.82005 Boehringer Ingelheim Investigational Site
-
Hwasun, Korea, Republic of
- 1200.23.82006 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 1200.23.82001 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 1200.23.82002 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 1200.23.82003 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republic of
- 1200.23.82004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amsterdam, Netherlands
- 1200.23.31002 Boehringer Ingelheim Investigational Site
-
Groningen, Netherlands
- 1200.23.31001 Boehringer Ingelheim Investigational Site
-
Helmond, Netherlands
- 1200.23.31003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Singapore, Singapore
- 1200.23.65001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, Spain
- 1200.23.3405 Boehringer Ingelheim Investigational Site
-
Cruces, Spain
- 1200.23.3404 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 1200.23.3401 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 1200.23.3403 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 1200.23.3406 Boehringer Ingelheim Investigational Site
-
Valencia, Spain
- 1200.23.3402 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Taichung, Taiwan
- 1200.23.88604 Taichung Veterans General Hospital
-
Taichung, Taiwan
- 1200.23.88605 China Medical University Hospital
-
Tainan, Taiwan
- 1200.23.88606 National Cheng Kung University Hospital
-
Taipei, Taiwan
- 1200.23.88601 National Taiwan University Hospital
-
Taipei, Taiwan
- 1200.23.88602 Veterans General Hospital
-
Taipei, Taiwan
- 1200.23.88607 Tri-Service General Hospital
-
Taoyuan, Taiwan
- 1200.23.88603 Chang Gung Memorial Hosp-Linkou
-
-
-
-
-
Chiangmai, Thailand
- 1200.23.66001 Boehringer Ingelheim Investigational Site
-
Pathumwan, Bangkok, Thailand
- 1200.23.66003 Boehringer Ingelheim Investigational Site
-
Songkla, Thailand
- 1200.23.66002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Dundee, United Kingdom
- 1200.23.4404 Boehringer Ingelheim Investigational Site
-
Edinburgh, United Kingdom
- 1200.23.4403 Boehringer Ingelheim Investigational Site
-
Glasgow, United Kingdom
- 1200.23.4401 Boehringer Ingelheim Investigational Site
-
London, United Kingdom
- 1200.23.4405 Boehringer Ingelheim Investigational Site
-
Sutton, United Kingdom
- 1200.23.4406 Boehringer Ingelheim Investigational Site
-
-
-
-
Arizona
-
Kingman, Arizona, United States
- 1200.23.038 Boehringer Ingelheim Investigational Site
-
-
Arkansas
-
Fayetteville, Arkansas, United States
- 1200.23.046 Boehringer Ingelheim Investigational Site
-
-
California
-
Anaheim, California, United States
- 1200.23.027 Boehringer Ingelheim Investigational Site
-
Berkeley, California, United States
- 1200.23.028 Boehringer Ingelheim Investigational Site
-
Modesto, California, United States
- 1200.23.029 Boehringer Ingelheim Investigational Site
-
Montebello, California, United States
- 1200.23.045 Boehringer Ingelheim Investigational Site
-
Orange, California, United States
- 1200.23.009 Boehringer Ingelheim Investigational Site
-
Palm Springs, California, United States
- 1200.23.026 Boehringer Ingelheim Investigational Site
-
-
Florida
-
North Miami Beach, Florida, United States
- 1200.23.024 Boehringer Ingelheim Investigational Site
-
-
New York
-
New York, New York, United States
- 1200.23.020 Boehringer Ingelheim Investigational Site
-
Valhalla, New York, United States
- 1200.23.013 Boehringer Ingelheim Investigational Site
-
-
Utah
-
Salt lake City, Utah, United States
- 1200.23.056 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Renton, Washington, United States
- 1200.23.039 Boehringer Ingelheim Investigational Site
-
Seattle, Washington, United States
- 1200.23.050 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with pathologic confirmation of NSCLC Stage III-B (with pleural effusion) or Stage IV adenocarcinoma who have failed at least one but not more than two lines of cytotoxic chemotherapy (including adjuvant chemotherapy). One of the chemotherapy regimens must have been platinum-based.
- Progressive disease following at least 12 weeks of treatment with erlotinib (Tarceva®) or gefitinib (Iressa®)
- Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2
- Patients with at least one tumor lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension with longest diameter to be recorded as >20 mm using conventional techniques or >10 mm with spiral CT scan
- Male and female patients age >18 years
- Life expectancy of at least three (3) months
- Written informed consent that is consistent with ICH-GCP guidelines
Exclusion criteria:
- Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of treatment Day 1
- Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks
- Active brain metastases
- Significant or recent acute gastrointestinal disorders with diarrhea
- Patients who have any other life-threatening illness or organ system dysfunction,
- Other malignancies diagnosed within the past five (5) years
- Radiotherapy within the past 2 weeks prior to treatment
- History of clinically significant or uncontrolled cardiac disease
- Adequate ANC and platelet count
- Adequate liver and kidney function
- Patients with any serious active infection including known HIV, active hepatitis B or active hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Patients receive placebo once daily
|
Patients receive placebo once daily
|
Experimental: BIBW 2992
Patients receive BIBW 2992 tablets once daily
|
Patients receive afatinib tablets once daily, and can reduce dose for adverse event management.
Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: From randomization until death or the last patient out date, an average of 12 months
|
Overall survival was the duration from the date of randomization to the date of death. Patients who were alive were censored at the last contact date prior to the database lock. For the primary analysis 11 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Primary analysis data cut-off date was 08 July 2010. For the final analysis 13 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Final analysis data cut-off date was 04 October 2013. |
From randomization until death or the last patient out date, an average of 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months
|
PFS is defined as time from randomisation to disease progression or death whichever occurs first.
Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).
|
From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months
|
Objective Response Rate (OR)
Time Frame: From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months
|
OR is defined as complete response (CR) and partial response (PR).
Assessed by central independent review according to RECIST 1.0.
|
From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Afatinib
Other Study ID Numbers
- 1200.23
- 2007-005983-28 (EudraCT Number: EudraCT)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States